Santen Pharmaceutical Co., Ltd. (SNPHF)
Santen Pharmaceutical Co., Ltd. operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Osaka, OS, JP. The stock last traded at $13.05, up 0.00% on the session, giving a market capitalisation of $4.20B. On trailing twelve-month figures it carries a trailing P/E of 16.54, a net margin of 13.3%. Its beta of 0.24 implies it has historically moved less than the broad market.
Santen Pharmaceutical Co., Ltd. is a global enterprise specializing in the research, development, manufacturing, and commercialization of pharmaceuticals and medical devices. Headquartered in Osaka, Japan, its core focus lies in ophthalmology. The company boasts a robust pipeline of treatments for various eye conditions. For glaucoma and ocular hypertension, its offerings include DE-111 and DE-130A, both in Phase III clinical trials; DE-117, available in Japan; DE-126, currently in Phase IIb development; and DE-128, which is marketed in Europe and undergoing Phase II/III trials in the United States. Santen also addresses other ophthalmic conditions: DE-114A for allergic conjunctivitis, DE-076C for vernal keratoconjunctivitis, and DE-109, which is in Phase III development for uveitis. Its pipeline further includes treatments for myopia, such as DE-127 (in Phase II/III in Japan and Phase III across Asia) and STN1013400 (in Phase I). Additionally, DE-089C has successfully completed Phase III clinical trials for dry eye treatment. Beyond prescription medications, Santen also provides over-the-counter (OTC) pharmaceutical products. Founded in Osaka, Japan, in 1890, the company adopted its current name, Santen Pharmaceutical Co., Ltd., in 1958, having previously operated as Santendo Pharmaceutical Co., Ltd.
Santen Pharmaceutical Co., Ltd. is most often compared with the following Healthcare names: